Repeat hepatectomy for pediatric recurrent chemotherapy-resistant hepatoblastoma: a report of 18 cases

[1]  A. Rangaswami,et al.  Current Approaches in Hepatoblastoma—New Biological Insights to Inform Therapy , 2022, Current Oncology Reports.

[2]  C. Rodríguez-Galindo,et al.  Small Cell Undifferentiated Histology Does Not Adversely Affect Outcome in Hepatoblastoma: A Report From the Children's Oncology Group (COG) AHEP0731 Study Committee. , 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  Yukichi Tanaka,et al.  Feasibility of dose‐dense cisplatin‐based chemotherapy in Japanese children with high‐risk hepatoblastoma: Analysis of the JPLT3‐H pilot study , 2021, Pediatric blood & cancer.

[4]  S. Alexopoulos,et al.  Management of hepatoblastoma in the United States: Can we do better? , 2021, Surgery.

[5]  Mio Tanaka,et al.  Pilot study of the combination of sorafenib and fractionated irinotecan in pediatric relapse/refractory hepatic cancer (FINEX pilot study) , 2020, Pediatric blood & cancer.

[6]  Yukichi Tanaka,et al.  Outcome and Late Complications of Hepatoblastomas Treated Using the Japanese Study Group for Pediatric Liver Tumor 2 Protocol. , 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  T. Pawlik,et al.  Repeat hepatectomy for patients with early and late recurrence of hepatocellular carcinoma: A multicenter propensity score matching analysis. , 2019, Surgery.

[8]  G. Tiao,et al.  Surgical management of locally-advanced and metastatic hepatoblastoma. , 2019, Seminars in pediatric surgery.

[9]  T. Pawlik,et al.  Long-term Effects of Repeat Hepatectomy vs Percutaneous Radiofrequency Ablation Among Patients With Recurrent Hepatocellular Carcinoma: A Randomized Clinical Trial. , 2019, JAMA oncology.

[10]  C. Rodríguez-Galindo,et al.  Minimal adjuvant chemotherapy for children with hepatoblastoma resected at diagnosis (AHEP0731): a Children's Oncology Group, multicentre, phase 3 trial. , 2019, The Lancet. Oncology.

[11]  S. Alexopoulos,et al.  Contemporary management of hepatoblastoma , 2019, Current opinion in organ transplantation.

[12]  J. Marin,et al.  Mechanisms of Anticancer Drug Resistance in Hepatoblastoma , 2019, Cancers.

[13]  K. Hasegawa,et al.  Salvage liver transplantation or repeat hepatectomy for recurrent hepatocellular carcinoma: an intent-to-treat analysis , 2018, HPB.

[14]  B. Morland,et al.  2017 PRETEXT: radiologic staging system for primary hepatic malignancies of childhood revised for the Paediatric Hepatic International Tumour Trial (PHITT) , 2018, Pediatric Radiology.

[15]  K. Hasegawa,et al.  Salvage liver transplantation or repeat hepatectomy for recurrent hepatocellular carcinoma: An intent‐to‐treat analysis , 2017, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[16]  Yukichi Tanaka,et al.  Risk-stratified staging in paediatric hepatoblastoma: a unified analysis from the Children's Hepatic tumors International Collaboration. , 2017, The Lancet. Oncology.

[17]  R. Venkatramani,et al.  Effect of neoadjuvant chemotherapy on resectability of stage III and IV hepatoblastoma , 2015, The British journal of surgery.

[18]  E. Hiyama,et al.  Hepatoblastoma state of the art: pathology, genetics, risk stratification, and chemotherapy , 2014, Current opinion in pediatrics.

[19]  B. Morland,et al.  Dose-dense cisplatin-based chemotherapy and surgery for children with high-risk hepatoblastoma (SIOPEL-4): a prospective, single-arm, feasibility study , 2013, The Lancet. Oncology.

[20]  G. Perilongo,et al.  Relapses in hepatoblastoma patients: clinical characteristics and outcome--experience of the International Childhood Liver Tumour Strategy Group (SIOPEL). , 2013, European journal of cancer.

[21]  W. Furman,et al.  Current and Future Management Strategies for Relapsed or Progressive Hepatoblastoma , 2012, Pediatric Drugs.

[22]  G. Perilongo,et al.  Successful treatment of childhood high-risk hepatoblastoma with dose-intensive multiagent chemotherapy and surgery: final results of the SIOPEL-3HR study. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  S. Kondo,et al.  Outcome of hepatoblastomas treated using the Japanese Study Group for Pediatric Liver Tumor (JPLT) protocol-2: report from the JPLT , 2010, Pediatric Surgery International.

[24]  S. Warmann,et al.  Drug resistance in hepatoblastoma. , 2007, Current pharmaceutical biotechnology.

[25]  N. Demartines,et al.  Classification of Surgical Complications: A New Proposal With Evaluation in a Cohort of 6336 Patients and Results of a Survey , 2004, Annals of Surgery.

[26]  H. Mugishima,et al.  Analysis of treatment outcome for children with recurrent or metastatic hepatoblastoma , 2003, Pediatric Surgery International.

[27]  신동훈,et al.  성인에서 발생한 Hepatoblastoma , 1999 .